.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD27_MetforminLinagliptinAndEmpaglifl.MetforminLinagliptinAndEmpaglifl .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD27_MetforminLinagliptinAndEmpaglifl.MetforminLinagliptinAndEmpaglifl| name: | MetforminLinagliptinAndEmpagliflozin |
| ATC code: | A10BD27 | route: | oral |
| n-compartments | 1 |
A fixed-dose combination oral antidiabetic medication containing metformin (a biguanide that decreases hepatic glucose production and increases insulin sensitivity), linagliptin (a dipeptidyl peptidase-4 inhibitor enhancing incretin effect), and empagliflozin (a sodium-glucose co-transporter-2 inhibitor promoting urinary glucose excretion). Used in the management of type 2 diabetes mellitus in adults insufficiently controlled on metformin together with at least one of the other components. The combination is approved and marketed under several brands.
Population pharmacokinetic estimates based on standard published values for each component in healthy adults under typical oral dosing. No dedicated peer-reviewed population PK study for the fixed-dose triple combination was located; parameters estimated from individual component data.